SHARE PRICE > View All Stock Detailed Share Information Latest News Molecular Partners Presents Positive Interim Safety and Mechanistic Data From Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors Molecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology Meeting Molecular Partners Announces Upcoming Participation in Investor and Scientific Conferences > View All News All News Upcoming Events December 10, 2022 from 7:30 PM to 9:30 PM CST Molecular Partners to Host 64th Annual ASH Meeting & Exposition Reception March 9, 2023 Full-year results 2022 April 4, 2023 Annual General Meeting > View All Events All Events Latest Presentation November 15, 2022 MP Corporate Presentation September 2, 2022 MP Corporate Presentation August 26, 2022 H1 2022 Corporate Highlights and Financials > View All Presentations All Presentations Latest Financial Documents October 27, 2022 Q3 2022 Financial Statement August 25, 2022 Half Year Report 2022 May 12, 2022 Q1 2022 Financial Statement > View All Reports All Annual Report Seth Lewis, SVP Investor Relations, Communications and Strategy Contact Seth STAY INFORMED Subscribe to email alerts of your choosing SUBSCRIBE Institutional investors: REQUEST 1-1 / CALL powered by schedulR
Molecular Partners Presents Positive Interim Safety and Mechanistic Data From Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors
Molecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology Meeting
December 10, 2022 from 7:30 PM to 9:30 PM CST Molecular Partners to Host 64th Annual ASH Meeting & Exposition Reception
